Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA Office of Oncology Drug Products Director Richard Pazdur plans to convene an advisory committee meeting to clarify standards for use of progression-free survival data, a move prompted by industry's aggressive adoption of the surrogate endpoint and, more broadly, the gradual decline in the level of drug benefit that sponsors seek to use in support of a cancer drug approval

You may also be interested in...



The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival

Submitting an NDA based on progression-free survival when other drugs for the indication have been approved on the basis of overall survival benefits is a risky proposition, but GlaxoSmithKline was confident the magnitude of Mekinist and Tafinlar’s PFS effect in metastatic melanoma would make the findings clinically relevant.

Statistical Significance Does Not Prove Clinical Relevance, FDA Says

Having statistically significant trial results does not mean they are clinically meaningful

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel